| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa6a8dbd6467e560cd0ec019fe7d722a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
1999-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b94397f75fea9f4837f0b6d26ec9af9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b6e9429a842cf803e846897046086e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71aecf707b5dcf8eda6268921d28f6c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_784fe69ea994cb8b3025ddc8514d4620 |
| publicationDate |
2009-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2087889-A3 |
| titleOfInvention |
Controlled release oral tablet having a unitary core |
| abstract |
Metformin or a pharmaceutically acceptable salt thereof for use in providing continuous and non-pulsating plasma levels of an antihyperglycemic drug with a peak plasma level within 8-12 hours after administration when administered with or shortly after the evening meal in a controlled release pharmaceutical tablet exhibiting the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37 °C: n- after 2 hours 0-25% of the drug is released; n- after 4 hours 10-45% of the drug is released; n- after 8 hours 30-90% of the drug is released; n- after 12 hours not less than 50% of the drug is released; n- after 16 hours not less than 60% of the drug is released; and n- after 20 hours not less than 70% of the drug is released. |
| priorityDate |
1998-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |